Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research note issued on Friday, The Fly reports.
A number of other analysts have also commented on the stock. JPMorgan Chase & Co. lowered shares of Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a research note on Tuesday. Bank of America lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “neutral” rating in a research note on Monday, December 5th. Berenberg Bank decreased their price target on shares of Bayer Aktiengesellschaft from €76.00 ($80.85) to €70.00 ($74.47) and set a “buy” rating for the company in a research note on Monday, November 14th. Finally, Societe Generale reduced their target price on shares of Bayer Aktiengesellschaft from €69.00 ($73.40) to €54.00 ($57.45) and set a “hold” rating for the company in a research note on Wednesday, November 9th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $78.00.
Bayer Aktiengesellschaft Stock Down 0.1 %
Bayer Aktiengesellschaft stock opened at $13.07 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.16 and a debt-to-equity ratio of 0.95. Bayer Aktiengesellschaft has a 12-month low of $11.41 and a 12-month high of $18.45. The firm’s fifty day moving average is $13.51 and its 200 day moving average is $13.49. The company has a market capitalization of $51.36 billion, a PE ratio of 6.08, a PEG ratio of 1.25 and a beta of 1.16.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bayer Aktiengesellschaft wasn’t on the list.
While Bayer Aktiengesellschaft currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
